Tissue angiotensin-converting enzyme (ACE) was measured in 60 patients with psoriasis and in 20 healthy individuals. According to clinical forms of psoriasis, patients were further divided into three groups: psoriasis with solitary lesions (n=20), psoriasis with multiple disseminated lesions (n=20) and erythrodermic psoriasis (n=20). The tissue ACE activity was determined before and after therapy, by the spectrophotometric method using hippuryl-l-histidyl-l-leucine as a substrate. The enzyme activity is expressed in units: 1 U corresponds to 1 nmol of hippuric acid released by hydrolysis of hippuryl-l-histidyl-l-leucine per minute and 50 mg of the tissue. Before therapy, tissue ACE activity was significantly increased in patients with psoriasis (4,14+/-0,34; X+/-SEM) in comparison to healthy individuals (1,86+/-0,16). The greatest increase in tissue ACE activity was observed in patients with erythrodermic psoriasis (4,72+/-0,65), followed by those with multiple disseminated lesions (4,24+/-0,63) and solitary psoriatic lesions (3,47+/-0,48). After therapy, serum ACE activity was significantly decreased in all clinical forms of the disease. Determination of tissue ACE activity might be a good non-specific parameter for assessment therapeutic effects.

In order to study concentration of nitric oxide (NO) in the saliva of patients with Parkinson's disease (PD), we measured the concentration of its stable metabolite nitrite (NO(2)-) in the saliva of these patients and healthy subjects. We analyzed saliva flow rate and salivary NO concentrations in 16 subjects with Parkinson's disease and in 16 healthy subjects. Concentration of nitrite was determined by colorimetric method using Griess reaction. Saliva flow rate was significantly lower in patients with Parkinson's disease (0.2+/-0.03 mL/min; X+/-SEM) than in healthy subjects. Salivary NO(2)-concentration was significantly lower (5.02+/-0.64) than in healthy individuals (22.39+/-1.24, p<0.0001).

We investigated serum concentration of C-reactive protein (CRP) and measures of adiposity in 30 patients with type 2 diabetes mellitus (15 male, 15 female) and 30 age and sex-matched apparently healthy subjects. CRP concentration was determined by laser nephelometry (BN II Analyzer) and CardioPhase high-sensitivity CRP (DADE BEHRING) was used as reagent which consists of polystyrene particles coated with mouse monoclonal antibodies to CRP. Results have shown that serum CRP concentration in patients with type 2 diabetes mellitus was statistically significantly higher compared to control group of healthy subjects (p<0,05). Body mass index (BMI) correlated significantly with serum concentration of CRP in patients with type 2 diabetes mellitus (r=0.614; p<0.001). Statistically significant positive correlation was also found between waist to hip ratio and serum CRP concentration in patients with type 2 diabetes mellitus (r=0.426; p<0.05). Elevated serum CRP concentration in patients with type 2 diabetes mellitus is probably caused by the presence of chronic low-grade inflammation in these patients. It is possible that determined increase of CRP concentration reflects activation of innate immune system components in patients with type 2 diabetes mellitus. Implications of established association between measures of adiposity and serum CRP level in type 2 diabetes mellitus remain unclear.

No abstract